Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Iwata · SciRah

Researcher profile · Semantic Scholar

H. Iwata

Share profile

H. Iwata — researcher profile on SciRah

h-index: 85
Works: 693
Citations: 46K

Most-cited papers

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
J. Cortés, Sung-Bae Kim, Wei-Pang Chung, S. Im +20 more
2022New England Journal of Medicine939 citations Open access
Semantic Scholar
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
J. Cortés, H. Rugo, D. Cescon, S. Im +15 more
2022New England Journal of Medicine898 citations Open access
Semantic Scholar
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
S. Hurvitz, R. Hegg, Wei-Pang Chung, S. Im +26 more
2022The Lancet530 citations Open access
Semantic Scholar
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
M. Cristofanilli, H. Rugo, S. Im, D. Slamon +16 more
2022Clinical Cancer Research175 citations Open access
Semantic Scholar
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
I. Krop, N. Masuda, T. Mukohara, S. Takahashi +21 more
2023Journal of Clinical Oncology96 citations Open access
Semantic Scholar
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
N. Turner, C. Huang-Bartlett, K. Kalinsky, M. Cristofanilli +11 more
2023Future Oncology87 citations Open access
Semantic Scholar
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
S. Tolaney, A. Chan, K. Petráková, S. Delaloge +12 more
2023Journal of Clinical Oncology66 citations Open access
Semantic Scholar
Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study)
T. Akechi, T. Yamaguchi, Megumi Uchida, Fuminobu Imai +15 more
2022Journal of Clinical Oncology64 citations Open access
Semantic Scholar
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
J. Masuda, H. Sakai, J. Tsurutani, Y. Tanabe +18 more
2023Journal for ImmunoTherapy of Cancer62 citations Open access
Semantic Scholar
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
S. Loi, R. Salgado, P. Schmid, J. Cortés +19 more
2023JCO Precision Oncology56 citations
Semantic Scholar
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
I. Krop, N. Masuda, T. Mukohara, S. Takahashi +16 more
2022Journal of Clinical Oncology55 citations
Semantic Scholar
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer
Masato Takahashi, J. Cortés, R. Dent, L. Pusztai +16 more
2023JAMA Network Open49 citations Open access
Semantic Scholar
Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
S. Hurvitz, Sung-Bae Kim, Wei-Pang Chung, S. Im +16 more
2022Cancer Research43 citations
Semantic Scholar
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
A. Yoshimura, I. Imoto, H. Iwata
2022International Journal of Molecular Sciences39 citations Open access
Semantic Scholar
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
F. Holmes, B. Moy, S. Delaloge, S. Chia +23 more
2023European Journal of Cancer33 citations Open access
Semantic Scholar
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
E. Mayer, C. Fesl, D. Hlauschek, L. García-Estévez +29 more
2022Journal of Clinical Oncology28 citations Open access
Semantic Scholar
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
P. Neven, H. Rugo, S. Tolaney, H. Iwata +7 more
2021Breast Cancer Research28 citations Open access
Semantic Scholar
VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
M. Campone, Cynthia X. Ma, M. de Laurentiis, H. Iwata +9 more
2023Journal of Clinical Oncology27 citations
Semantic Scholar
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study
Kiyo Tanaka, N. Masuda, N. Hayashi, Yasuaki Sagara +13 more
2021Breast Cancer27 citations Open access
Semantic Scholar
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies
S. Takahashi, H. Bando, Ichiro Kinoshita, S. Modi +8 more
2024Japanese Journal of Clinical Oncology26 citations Open access
Semantic Scholar
Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics.
G. Jia, Jie Ping, Xiang Shu, Yaohua Yang +52 more
2022American Journal of Human Genetics26 citations Open access
Semantic Scholar
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
A. Bardia, J. Cortés, S. Hurvitz, S. Delaloge +8 more
2022Therapeutic Advances in Medical Oncology24 citations Open access
Semantic Scholar
Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
M. Hattori, N. Masuda, T. Takano, K. Tsugawa +11 more
2023Cancer Medicine23 citations Open access
Semantic Scholar
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
M. Toi, K. Inoue, N. Masuda, H. Iwata +11 more
2021Cancer Science23 citations Open access
Semantic Scholar
Comorbid insomnia among breast cancer survivors and its prediction using machine learning: a nationwide study in Japan
Taro Ueno, Daisuke Ichikawa, Y. Shimizu, Tomomi Narisawa +5 more
2021Japanese Journal of Clinical Oncology20 citations Open access
Semantic Scholar
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
G. Pfeiler, D. Hlauschek, E. Mayer, C. Deutschmann +47 more
2023Journal of Clinical Oncology19 citations
Semantic Scholar
Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
M. Sawaki, Y. Muramatsu, K. Togo, H. Iwata
2023Breast18 citations Open access
Semantic Scholar
Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
Yutaka Yamamoto, H. Iwata, N. Taira, N. Masuda +18 more
2022Cancer Science18 citations Open access
Semantic Scholar
Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
E. Hamilton, Vanessa Petry Helena Bragaia, W. Yeo, Sung-Bae Kim +14 more
2022Journal of Clinical Oncology15 citations
Semantic Scholar
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
S. Sasada, Naoto Kondo, Hiroya Hashimoto, Yuko Takahashi +16 more
2023Breast Cancer Research and Treatment14 citations Open access
Semantic Scholar
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
H. Iwata, R. Nakamura, N. Masuda, T. Yamashita +17 more
2022Japanese Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Oncology care providers’ awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: a nationwide cross-sectional web-based survey
Y. Shimizu, Katsunori Tsuji, E. Ochi, Ryo Okubo +6 more
2021Supportive Care in Cancer13 citations Open access
Semantic Scholar
An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
I. Krop, H. Wildiers, S. Hurvitz, J. Cortés +12 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
S. Saji, N. Taira, M. Kitada, T. Takano +16 more
2022The Lancet Oncology10 citations
Semantic Scholar
Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)
Akimitsu Maeda, Hitoshi Ando, K. Irie, Naoya Hashimoto +6 more
2023Anticancer Research9 citations Open access
Semantic Scholar
Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
H. Kotani, N. Masuda, T. Yamashita, Y. Naito +9 more
2022Breast Cancer9 citations Open access
Semantic Scholar
Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
M. Sawaki, N. Taira, Y. Uemura, Tsuyoshi Saito +18 more
2022Breast9 citations Open access
Semantic Scholar
Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
K. Tamura, T. Mukohara, K. Yonemori, Yumiko Kawabata +3 more
2023Breast Cancer8 citations Open access
Semantic Scholar
Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
S. Hurvitz, R. Hegg, Wei-Pang Chung, S. Im +16 more
2023Cancer Research8 citations
Semantic Scholar
Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease
F. André, S. Im, P. Neven, R. Baird +11 more
2022Cancer Research8 citations
Semantic Scholar
Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.
M. Sawaki, Y. Muramatsu, K. Togo, Thomas Laurent +1 more
2022Future Oncology8 citations Open access
Semantic Scholar
Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition
Tsunehisa Nomura, M. Kawai, Yuna Fukuma, Y. Koike +9 more
2023Breast Cancer7 citations Open access
Semantic Scholar
Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.
K. Nozawa, Daiki Takatsuka, Y. Endo, N. Horisawa +7 more
2022Critical reviews in oncology/hematology7 citations
Semantic Scholar
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
H. Iwata, Yutaka Yamamoto, Takehiko Sakai, Y. Hasegawa +11 more
2023Breast Cancer Research and Treatment6 citations Open access
Semantic Scholar
Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
N. Masuda, N. Kosaka, H. Iwata, M. Toi
2021International Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.
K. Nozawa, M. Sawaki, H. Iwata
2023The Lancet Oncology5 citations
Semantic Scholar
PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03
S. Im, Bing-He Xu, Sung-Bae Kim, Wei-Pang Chung +16 more
2022Annals of Oncology5 citations Open access
Semantic Scholar
The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial
A. Kataoka, M. Sawaki, N. Horisawa, H. Kotani +9 more
2023Annals of Surgical Oncology4 citations
Semantic Scholar
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.
H. Rugo, M. Oliveira, S. Howell, F. Dalenc +16 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use
Y. Endo, A. Yoshimura, M. Sawaki, M. Hattori +8 more
2022Journal of Breast Cancer4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Masuda×15
Invite
N. Masuda — researcher profile on SciRah
S. Im×13
Invite
S. Im — researcher profile on SciRah
J. Cortés×12
Invite
J. Cortés — researcher profile on SciRah
S. Hurvitz×8
Invite
S. Hurvitz — researcher profile on SciRah

×8

Invite

M. Sawaki — researcher profile on SciRah

Invite

E. Hamilton — researcher profile on SciRah

Sung-Bae Kim×6

Invite

Sung-Bae Kim — researcher profile on SciRah

Yeon-Hee Park×6

Invite

Yeon-Hee Park — researcher profile on SciRah

Invite

J. Cathcart — researcher profile on SciRah

Masato Takahashi×6

Invite

Masato Takahashi — researcher profile on SciRah

Invite

K. Yonemori — researcher profile on SciRah

Yutaka Yamamoto×6

Invite

Yutaka Yamamoto — researcher profile on SciRah